Changes in Hepatic TRβ Protein Expression, Lipogenic Gene Expression, and Long-Chain Acylcarnitine Levels During

Kenji Ohba1, Rohit Anthony Sinha1, Brijesh Kumar Singh1

  • 11 Cardiovascular and Metabolic Disorders Program, Duke-NUS Medical School , Singapore, Singapore .

Abstract

Insights

Chronic thyroid hormone (TH) exposure desensitizes hepatic TRβ protein, leading to altered lipogenic gene expression and acylcarnitine levels after withdrawal. These changes persist despite normal thyroid-stimulating hormone (TSH) and TH levels, impacting hepatic metabolism.

Area of Science:

  • Endocrinology
  • Molecular Biology
  • Metabolomics

Background:

  • Thyroid hormone (TH) regulates hepatic metabolism, but desensitization and incomplete gene recovery occur after chronic exposure.
  • Understanding mechanisms behind hepatic gene desensitization and incomplete recovery is crucial for metabolic regulation.

Purpose of the Study:

  • To investigate the mechanisms of desensitization and incomplete recovery of hepatic target gene transcription after chronic TH treatment.
  • To assess the effects of these changes on hepatic metabolism.

Main Methods:

  • Adult male mice received daily triiodothyronine (T3) injections for 14 days, followed by 10 days of withdrawal.
  • Liver tissues were analyzed using quantitative reverse transcription polymerase chain reaction, Western blotting, and metabolomics.
  • Monocarboxylate transporter-8 (Mct8)-knockout mice were used to model chronic intrahepatic hyperthyroidism.

Main Results:

  • Chronic T3 treatment decreased hepatic TRβ protein, which persisted after withdrawal in wild-type and Mct8-knockout mice.
  • Hepatic lipogenic gene expression and acylcarnitine levels showed abnormalities after T3 withdrawal, despite normalized serum TSH and TH.
  • Long-chain acylcarnitine levels paradoxically increased after T3 withdrawal, contrasting with acute TH treatment effects.

Conclusions:

  • Decreased hepatic TRβ protein expression is a key finding after chronic T3 exposure.
  • Abnormalities in hepatic lipogenic gene expression and acylcarnitine levels post-withdrawal highlight tissue-specific metabolic adaptations.
  • Findings may explain variable clinical presentations in hyperthyroidism and recovery due to dissociated tissue and circulating hormone levels.